Reapplix gets US FDA green light for autologous cell-based wound therapy
This article was originally published in Clinica
Executive Summary
The increasingly heated regenerative medicine space is to welcome another new entrant in the US market, following FDA clearance of Reapplix’s 3C Patch System.